Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).-Reference-Cited by-同舟云学术

Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).

Published:2011-05-20 Issue:15_suppl Volume:29 Page:4521-4521
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Dubray B. M.,Beckendorf V.,Guerif S.,Le Prise E.,Reynaud-Bougnoux A.,Hannoun Levi J. M.,Nguyen T. D.,Hennequin C.,Cretin J.,Fayolle-Campana M.,Lagrange J.,Bachaud J.,Azria D.,Grangirard A.,Pommier P.,Simon J.,Harter V.,Habibian M.,

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2011.29.15_suppl.4521

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of Current Treatment Intensification Strategies for Prostate Cancer Patients;Cancers;2023-11-28

2. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation;Radiation Oncology;2017-09-07

3. Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer;Management of Prostate Cancer;2017

4. Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer;Advances in Radiation Oncology;2016-10

5. Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?;Cancer Medicine;2016-07-25